Bristol Myers Squibb's Camzyos Shows Sustained Efficacy Over Five…

Event summary

Bristol Myers Squibb presented five-year data from the EXPLORER-LTE study at ESC Congress 2026, reinforcing the long-term efficacy and safety of Camzyos (mavacamten) in symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
The study showed sustained reduction in left ventricular outflow tract (LVOT) obstruction and improved NYHA class in 69.6% of patients.
No new safety signals were observed, with mean left ventricular ejection fraction (LVEF) decreasing by 10.2% but remaining within the normal range.
Additional real-world data from COLLIGO-HCM and a German registry study further supported Camzyos' effectiveness across geographic populations.

The big picture

Bristol Myers Squibb's long-term data on Camzyos underscores its position as a standard of care for oHCM, addressing a serious condition affecting daily activities for many patients. The sustained efficacy and safety profile could reinforce its market leadership, while the real-world evidence supports broader clinical adoption. The findings come at a time when cardiovascular disease remains the leading cause of death worldwide, highlighting the need for effective, long-term treatments.

What we're watching

Market Penetration: Whether Bristol Myers Squibb can sustain the momentum of Camzyos' adoption, given its prescription by over 5,000 healthcare providers to more than 25,000 patients in the U.S. alone.
Regulatory Dynamics: How the long-term data will influence regulatory decisions in markets where Camzyos is not yet approved, potentially expanding its global reach.
Competitive Landscape: The pace at which competitors develop alternative treatments for oHCM, given the robust evidence base supporting Camzyos.